Panaxia

Company Overview

Snapshot

Founded in September 2009 by Dadi Segal, Panaxia operates with 51–200 employees. The company has raised $11.6M across 3 funding rounds from 7 investors. In March 2024, Panaxia was acquired by Barak Investment House.

Business overview

Panaxia Pharmaceutical Industries specializes in the research, development, and manufacturing of medical cannabis products. The company focuses on aligning medical cannabis with advanced formulation technologies and stringent pharmaceutical standards. Panaxia manufactures a variety of standardized medical cannabis products, including sublingual and oral tablets, metered-dose inhalers, creams, and suppositories. It serves the Health Tech & Life Sciences sector, specifically targeting the pharmaceutical and medical cannabis markets, and offers over 600 medical products across more than 30 international markets.

Strategic signal

This suggests a positive outlook on the company's value proposition and market position, even as it transitioned towards an acquisition.

Company Intelligence Q&A

What was a significant recent corporate event for Panaxia?

In March 2024, Panaxia was acquired by Barak Investment House, marking a significant exit for the company.

When did Panaxia complete its reverse merger?

In September 2019, Panaxia completed a reverse merger with Herodium Investments, which was listed on the TASE.